Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder

International Journal of Geriatric Psychiatry

Volumn 19, Issue 9, 2004, Pages 898-905

  Lasser, Robert A ^a   Bossie, Cynthia A ^a   Zhu, Young ^a   Gharabawi, Georges ^a   Eerdekens, Mariëlle ^b   Davidson, Michael ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Elderly; Long acting risperidone; Schizoaffective disorder; Schizophrenia

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LITHIUM; LONG ACTING DRUG; NEUROLEPTIC AGENT; PROPRANOLOL; RISPERIDONE;

AGED; ANXIETY DISORDER; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISORIENTATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EXCITABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART INFARCTION; HOSTILITY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; OPEN STUDY; PSYCHOSIS; RATING SCALE; RHINITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 4544383440     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1184     Document Type: Article

References (37)

1. Beasley CM, Dellva MA, Tamura RN, et al. 1999. Randomised double-bind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 174: 23-30.
2. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. 2001. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 62: 855-859.
3. Chouinard G, Lasser R, Bossie C, Zhu Y, Gharabawi G. 2003. Lower risk of tardive dyskinesia in patients with schizophrenia treated with a long-acting injectable atypical antipsychotic. Poster Presented at the International Congress on Schizophrenia Research, 29 March-2 April 2003, Colorado Springs, Colorado.
4. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. 1980. Extrapyramidal symptom rating scale. Can J Neurol Sci 7: 233.
5. Cramer JA, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49: 196-201.
6. Davidson M, Harvey PD, Powchik P, et al. 1995. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 152: 197-207.
7. Davidson M, Harvey PD, Vervarcke J. 2000. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 15: 506-514.
8. Davis JM, Kane JM, Marder SR, et al. 1993. Dose response of prophylactic antipsychotics. J Clin Psychiatry 54(Suppl.): 24-30.
9. Davis JM, Matalon L, Watanabe MD, Blake L. 1994. Depot antipsychotic drugs: place in therapy. Drugs 47: 741-773.
10. Eerdekens M, Rasmussen M, Vermeulen A, Lowenthal R, Van Peer A. 2000. Kinetics and safety of a novel risperidone depot. Presented at American Psychiatric Association 2000 Annual Meeting, 13-18 May 2000; Chicago, IL. New Research Abstracts, NR669.
11. Farah A. 2002. Reduction of tardive dyskinesia with quetiapine. Schizophr Res 47: 309-310.
12. Federal Register Notice. 2001. Guidance for Industry on Content and Format of Geriatric Labeling 51053-51054.
13. Fleischhacker WW, Eerdekens M, Karcher K, et al. 2003. Treatment of schizophrenia with long-acting risperidone: a 12-month evaluation of the first long-acting injectable second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257.
14. Fleischhacker WW, Lemmens P, van Baelen B. 2001. A qualitative assessment of the neurological safety of antipsychotic drugs: an analysis of a risperidone database. Pharmacopsychiatry 34: 104-110.
15. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. 2003. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 64: 726-730.
16. Glazer WM, Kane JM. 1992. Depot neuroleptic therapy: an under-utilized treatment option. J Clin Psychiatry 53: 426-433.
17. Guy E (ed.). 1976. Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76. National Institutes of Mental Health, Department of Health, Education, and Welfare: Rockville, MD; 218-220.
18. Hay J. 1995. Complications at site of injection of depot neuroleptics. BMJ 311: 421.
19. Jeste DV. 1999. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 47: 716-719.
20. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. 2004. An international multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 11: 638-647.
21. Jeste DV, Caliguri MP, Paulsen JS, et al. 1995. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 52: 756-765.
22. Johnson D. 1990. Long-term drug treatment of psychosis: observations on some current issues. Int Rev Psychiatry 2: 341-353.
23. Johnson DA, Pasterski B, Ludlow JM, Street K, Taylor RD. 1983. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67: 339-352.
24. Kane JM, Aguglia E, Altamura AC, et al. 1998. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8: 55-66.
25. Kane JM, Eerdekens M, Lindenmayer J-P, Keith S, Lesem N, Karcher K. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132.
26. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
27. Lacro JP, Dunn LB, Dolder CR, Leckbanc SG, Jeste DV. 2002. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of the literature. J Clin Psychiatry 63: 892-909.
28. Lasser R, Rodriguez S, Bossie C, Gharabawi G, Kane JM. 2003. Core symptom remission in patients with schizophrenia receiving long-acting risperidone. American Psychiatric Association 2003 Annual meeting, San Francisco, CA, 17-22 May 2003. New Research Abstracts, NR528.
29. Madhusoodanan S, Brecher M, Brenner R, et al. 1999. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 7: 132-138.
30. Marder SR, Davis JM, Chouinard G. 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58: 538-546.
31. Masand PS. 2000. Side effects of antipsychotics in the elderly. J Clin Psychiatry 61(Suppl. 8): 43-49.
32. Svarstad BL, Shireman TI, Sweeney JK. 2001. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 52: 805-811.
33. Tariot PN, Ismail MS. 2002. Use of quetiapine in elderly patients. J Clin Psychiatry 63(Suppl. 13): 21-26.
34. Ware J, Kosinski M, Keller S. 1994. SF-36 Physical and Mental Health Summary Scales: A User's Manual. The Health Institute: Boston, MA.
35. Weiden P, Zygmunt A. 1997. Medication noncompliance in schizophrenia. J Pract Psychiatry Behav Health 3: 106-110.
36. Weiden PJ, Olfson M. 1995. Cost of relapse in schizophrenia. Schizophr Bull 21: 419-429.
37. Wyatt RJ. 1991. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17: 325-351.